Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.2430
+0.0064 (2.70%)
At close: Feb 23, 2026, 4:00 PM EST
0.2479
+0.0049 (2.02%)
After-hours: Feb 23, 2026, 4:32 PM EST
Akari Therapeutics, Employees
As of December 31, 2024, Akari Therapeutics, had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,752,444
Market Cap
11.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | 9 | -1 | -10.00% | 9 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 40 |
| KALA BIO | 38 |
| Imunon | 25 |
| Soligenix | 16 |
| Iterum Therapeutics | 9 |
| Phio Pharmaceuticals | 5 |
| Pulmatrix | 2 |
AKTX News
- 5 days ago - Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - GlobeNewsWire
- 12 days ago - Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript - Seeking Alpha
- 12 days ago - Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline - GlobeNewsWire
- 18 days ago - Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - GlobeNewsWire
- 6 weeks ago - Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewsWire
- 6 weeks ago - Akari Therapeutics to Present at the 2026 Biotech Showcase - GlobeNewsWire
- 7 weeks ago - Akari Therapeutics Issues 2025 End of Year Letter to Shareholders - GlobeNewsWire